Hong Kong
· Delayed Price · Currency is HKD Innovent Biologics Statistics
Total Valuation
HKG:1801 has a market cap or net worth of HKD 75.68 billion. The enterprise value is 70.31 billion.
| Market Cap | 75.68B |
| Enterprise Value | 70.31B |
Important Dates
The last earnings date was Tuesday, March 25, 2025.
| Earnings Date | Mar 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:1801 has 1.64 billion shares outstanding. The number of shares has increased by 4.35% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.64B |
| Shares Change (YoY) | +4.35% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 6.76% |
| Owned by Institutions (%) | 40.00% |
| Float | 1.43B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 204.31 |
| PS Ratio | 7.50 |
| PB Ratio | 5.40 |
| P/TBV Ratio | 6.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -698.16 |
| EV / Sales | 7.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.35 |
| Quick Ratio | 2.08 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.17 |
Financial Efficiency
Return on equity (ROE) is -0.74% and return on invested capital (ROIC) is -2.94%.
| Return on Equity (ROE) | -0.74% |
| Return on Assets (ROA) | -2.24% |
| Return on Invested Capital (ROIC) | -2.94% |
| Return on Capital Employed (ROCE) | -4.39% |
| Revenue Per Employee | 1.77M |
| Profits Per Employee | -17,795 |
| Employee Count | 5,659 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.16% in the last 52 weeks. The beta is 0.37, so HKG:1801's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +20.16% |
| 50-Day Moving Average | 37.83 |
| 200-Day Moving Average | 39.32 |
| Relative Strength Index (RSI) | 67.40 |
| Average Volume (20 Days) | 15,855,722 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:1801 had revenue of HKD 10.03 billion and -100.70 million in losses. Loss per share was -0.06.
| Revenue | 10.03B |
| Gross Profit | 7.46B |
| Operating Income | -804.38M |
| Pretax Income | -83.67M |
| Net Income | -100.70M |
| EBITDA | -511.10M |
| EBIT | -804.38M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 8.39 billion in cash and 3.01 billion in debt, giving a net cash position of 5.38 billion or 3.28 per share.
| Cash & Cash Equivalents | 8.39B |
| Total Debt | 3.01B |
| Net Cash | 5.38B |
| Net Cash Per Share | 3.28 |
| Equity (Book Value) | 13.96B |
| Book Value Per Share | 8.55 |
| Working Capital | 6.28B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 74.40%, with operating and profit margins of -8.02% and -1.00%.
| Gross Margin | 74.40% |
| Operating Margin | -8.02% |
| Pretax Margin | -0.83% |
| Profit Margin | -1.00% |
| EBITDA Margin | -5.10% |
| EBIT Margin | -8.02% |
| FCF Margin | n/a |
Dividends & Yields
HKG:1801 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.35% |
| Shareholder Yield | -4.35% |
| Earnings Yield | -0.13% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |